COMP <GO>
AGMB vs ZURA // FREE CASH FLOW YIELD
AgomAb Therapeutics NV (NASDAQ) VS. Zura Bio Limited (Class A) (NASDAQ) • 15-METRIC TALLY: AGMB 1
— ZURA 1
■ METRIC PARITY
LAST: $7.95 (-0.13%) • MKT CAP: $391.5M
fcf-yield
—
LAST: $3.85 (-11.49%) • MKT CAP: $370.9M
fcf-yield
-17.51%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AGMB VS. ZURA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AGMB | ZURA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | — | -17.51% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 29.2 | 48.1 | -18.90 | ZURA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $391.5M | $370.9M | $20.7M | AGMB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AGMB REV | ZURA REV | AGMB GROSS % | ZURA GROSS % | AGMB FCF | ZURA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $0 | — | — | — | -$64.9M |
| FY 2024 | — | $0 | — | — | — | -$28.2M |
| FY 2023 | — | $0 | — | — | — | -$15.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AGMB // BETA —
ZURA // BETA —